{"id":27291,"date":"2021-03-25T12:25:32","date_gmt":"2021-03-25T10:25:32","guid":{"rendered":"https:\/\/www.asperbio.com\/?page_id=27291"},"modified":"2021-03-25T12:25:32","modified_gmt":"2021-03-25T10:25:32","slug":"statiin-seoselise-muopaatiaga-seotud-mutatsioonanaluus","status":"publish","type":"page","link":"https:\/\/www.asperbio.com\/et\/asper-pharmacogenetics\/statiin-seoselise-muopaatiaga-seotud-mutatsioonanaluus\/","title":{"rendered":"Statiin-seoselise m\u00fcopaatiaga seotud mutatsioonanal\u00fc\u00fcs"},"content":{"rendered":"

Statiin-seoselise m\u00fcopaatiaga seotud mutatsioonanal\u00fc\u00fcs<\/span><\/h2>\n
\n\n\n\n
Geen:<\/strong><\/td>\nSLCO1B1<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n\n\n\n
Metoodika:<\/strong><\/td>\nKodeeriva piirkonna sekveneerimine (Sanger)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n\n\n\n
Marker:<\/strong><\/td>\n1 (NM_006446.4:c.521T>C)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n\n\n\n
Testi valmimisaeg:<\/strong><\/td>\n2-4 n\u00e4dalat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n\n\n\n
N\u00f5uded proovi-materjalile:<\/strong><\/td>\n2-4 ml t\u00e4isverd antikoagulandiga EDTA (lilla korgiga katsuti)<\/p>\n

100 ng\u00a0DNA-d elueerituna TE, AE puhvris v\u00f5i steriilses vees, kontsentratsiooniga 100-250 ng\/\u00b5l
\nDNA saata toatemperatuuril v\u00f5i k\u00fclmutatuna. A260\/A280 suhe peaks olema 1.8-2.0. DNA peab agaroosgeelis pikkusmarkeri juuresolekul olema detekteeritav \u00fche tervikliku b\u00e4ndina.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\n\n\n
Tellimine:<\/strong><\/td>\nProovimaterjal saata koos saatekirjaga<\/a><\/strong><\/span> Asper Biogene laborisse<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n<\/div>\n

N\u00e4idustused geenitesti tegemiseks:<\/strong><\/p>\n

    \n
  1. Statiin-seoselise m\u00fcopaatia riski hindamine<\/li>\n
  2. Statiinide ravimidoosi m\u00e4\u00e4ramine<\/li>\n<\/ol>\n

    Statiinid<\/strong> inhibeerivad kolesterooli s\u00fcnteesi\u00a0ja aitavad kaasa madala tihedusega lipoproteiini\u00a0(LDL)\u00a0siduvate retseptorite juurdekasvule maksas, seel\u00e4bi alandades\u00a0m\u00e4rkimisv\u00e4\u00e4rselt LDL taset ning t\u00f5stes v\u00e4hesel m\u00e4\u00e4ral k\u00f5rge tihedusega lipoproteiini (HDL) taset vereplasmas. Selle omaduse t\u00f5ttu on statiinid esmane ravim\u00a0h\u00fcperkolesteroleemia\u00a0ja\u00a0koronaararteri\u00a0haiguste\u00a0puhul.<\/p>\n

    Vaatamata statiinide ohutusele ja efektiivsusele on t\u00e4heldatud, et peale aastast statiiniravi on 25% – 50% s\u00fcdame-veresoonkonna haiguste patsiente j\u00f5udnud\u00a0ravivastuse v\u00e4henemise\u00a0faasi. \u00a0Kuigi viimasega\u00a0v\u00f5ib olla seotud mitmeid tegureid, usuvad paljud eksperdid, et \u00fcheks faktoriks on erinevad k\u00f5rvalm\u00f5jud, sealhulgas\u00a0skeletilihaste m\u00fcrgistus, mille v\u00f5ib p\u00f5hjustada\u00a0v\u00e4hene statiiniravimite metabolism.<\/p>\n

    Statiin-seoselist m\u00fcopaatiat seostatakse\u00a0SLCO1B1<\/em> geeni NM_006446.4:c.521T>C (rs4149056) variandiga.\u00a0M\u00fcopaatia tekkerisk on oluliselt suurem patsientidel, kes saavad simvastatiini 80 mg v\u00f5rreldes teiste statiinidel p\u00f5hinevate ravimeetoditega, millel on sarnane LDL-kolesterooli (LDL-C) langetav toime.<\/p>","protected":false},"excerpt":{"rendered":"

    Statiin-seoselise m\u00fcopaatiaga seotud mutatsioonanal\u00fc\u00fcs Geen: SLCO1B1 Metoodika: Kodeeriva piirkonna sekveneerimine (Sanger) Marker: 1 (NM_006446.4:c.521T>C) Testi valmimisaeg: 2-4 n\u00e4dalat N\u00f5uded proovi-materjalile: 2-4 ml t\u00e4isverd antikoagulandiga EDTA (lilla korgiga katsuti) 100 ng\u00a0DNA-d elueerituna TE, AE puhvris v\u00f5i steriilses vees, kontsentratsiooniga 100-250 ng\/\u00b5l DNA saata toatemperatuuril v\u00f5i k\u00fclmutatuna. A260\/A280 suhe peaks olema 1.8-2.0. DNA peab agaroosgeelis pikkusmarkeri juuresolekul […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":27285,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-27291","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/27291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/comments?post=27291"}],"version-history":[{"count":1,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/27291\/revisions"}],"predecessor-version":[{"id":27292,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/27291\/revisions\/27292"}],"up":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/27285"}],"wp:attachment":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/media?parent=27291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}